Sanofi invests $180 million in Owkin’s AI to advance oncology pipeline
Sanofi invests $180 million equity in Owkin’s artificial intelligence (AI) and federated learning to advance oncology pipeline.
List view / Grid view
Sanofi invests $180 million equity in Owkin’s artificial intelligence (AI) and federated learning to advance oncology pipeline.
The acquisition will strengthen Merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate in trials for haematological malignancies and solid tumours.
The US FDA has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy), to treat triple-negative breast cancer in adult patients.
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...